315 related articles for article (PubMed ID: 15929107)
1. Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists.
Zumberg MS; Reddy S; Boyette RL; Schwartz RJ; Konrad TR; Lottenberg R
Am J Hematol; 2005 Jun; 79(2):107-13. PubMed ID: 15929107
[TBL] [Abstract][Full Text] [Related]
2. Use of hydroxyurea in children with sickle cell disease: what comes next?
Ohene-Frempong K; Smith-Whitley K
Semin Hematol; 1997 Jul; 34(3 Suppl 3):30-41. PubMed ID: 9317199
[TBL] [Abstract][Full Text] [Related]
3. Plasma and urine hydroxyurea levels might be useful in the management of adult sickle cell disease.
Bachir D; Hulin A; Huet E; Habibi A; Nzouakou R; El Mahrab M; Astier A; Galacteros F
Hemoglobin; 2007; 31(4):417-25. PubMed ID: 17994375
[TBL] [Abstract][Full Text] [Related]
4. Practice patterns of stroke screening and hydroxyurea use in children with sickle cell disease: a survey of health care providers.
Madden NA; Jones GL; Kalpatthi R; Woods G
J Pediatr Hematol Oncol; 2014 Aug; 36(6):e382-6. PubMed ID: 24714503
[TBL] [Abstract][Full Text] [Related]
5. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.
Iyamu EW; Cecil R; Parkin L; Woods G; Ohene-Frempong K; Asakura T
Br J Haematol; 2005 Nov; 131(3):389-94. PubMed ID: 16225659
[TBL] [Abstract][Full Text] [Related]
6. Effects of hydroxyurea treatment on cerebral oxygenation in adult patients with sickle cell disease: an open-label pilot study.
Tavakkoli F; Nahavandi M; Wyche MQ; Castro O
Clin Ther; 2005 Jul; 27(7):1083-8. PubMed ID: 16154487
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea treatment of sickle cell anemia in hospital-based practices.
Ferguson RP; Arun A; Carter C; Walker SD; Castro O
Am J Hematol; 2002 Aug; 70(4):326-8. PubMed ID: 12214583
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea treatment for sickle cell disease: impact on haematopoietic stem cell transplantation's outcome.
Brachet C; Azzi N; Demulder A; Devalck C; Gourdin A; Gulbis B; Klein A; Le PQ; Loop M; Sariban E; Ferster A
Bone Marrow Transplant; 2004 Apr; 33(8):799-803. PubMed ID: 14767501
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea for the treatment of sickle cell disease.
Segal JB; Strouse JJ; Beach MC; Haywood C; Witkop C; Park H; Wilson RF; Bass EB; Lanzkron S
Evid Rep Technol Assess (Full Rep); 2008 Mar; (165):1-95. PubMed ID: 18457478
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease.
Stallworth JR; Jerrell JM; Tripathi A
Am J Hematol; 2010 Oct; 85(10):795-7. PubMed ID: 20645429
[TBL] [Abstract][Full Text] [Related]
11. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria.
Adeyemo TA; Diaku-Akinwunmi IN; Ojewunmi OO; Bolarinwa AB; Adekile AD
Hemoglobin; 2019 May; 43(3):188-192. PubMed ID: 31462098
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea in children: present and future.
Vichinsky EP
Semin Hematol; 1997 Jul; 34(3 Suppl 3):22-9. PubMed ID: 9317198
[TBL] [Abstract][Full Text] [Related]
13. [Effect of hydroxyurea on hemoglobin S].
Torres AF; Eberle SE; Sciuccati G; Bonduel M
Medicina (B Aires); 2003; 63(2):140-2. PubMed ID: 12793083
[TBL] [Abstract][Full Text] [Related]
14. Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network.
Lanzkron S; Haywood C; Hassell KL; Rand C
J Natl Med Assoc; 2008 Aug; 100(8):968-73. PubMed ID: 18717150
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).
Sumoza A; de Bisotti R; Sumoza D; Fairbanks V
Am J Hematol; 2002 Nov; 71(3):161-5. PubMed ID: 12410569
[TBL] [Abstract][Full Text] [Related]
16. Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea.
Tripathi A; Jerrell JM; Stallworth JR
Pediatr Blood Cancer; 2011 Jan; 56(1):90-4. PubMed ID: 20922765
[TBL] [Abstract][Full Text] [Related]
17. DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea.
Friedrisch JR; Prá D; Maluf SW; Bittar CM; Mergener M; Pollo T; Kayser M; da Silva MA; Henriques JA; da Rocha Silla LM
Mutat Res; 2008 Jan; 649(1-2):213-20. PubMed ID: 17988936
[TBL] [Abstract][Full Text] [Related]
18. Perception to hydroxyurea therapy in patients with sickle cell disease: Report from 3 centers.
Korubo KI; Onodingene NM; Okoye HC; Omunakwe HE
Ann Afr Med; 2021; 20(2):127-131. PubMed ID: 34213480
[TBL] [Abstract][Full Text] [Related]
19. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea.
Lanzkron S; Haywood C; Segal JB; Dover GJ
Am J Hematol; 2006 Dec; 81(12):927-32. PubMed ID: 16924648
[TBL] [Abstract][Full Text] [Related]
20. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
Vicari P; Barretto de Mello A; Figueiredo MS
Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
